

Augnito Omni Launches No-Cost Pilots, with Free Cost-Benefit Analysis Report for All NHS Sites

Scribetech UK launches free Augnito Omni pilots for all NHS sites, complete with a complimentary cost-benefit analysis report.

LONDON, LONDON, UNITED KINGDOM, December 13, 2025 /EINPresswire.com/ -- [Scribetech UK](#), distributor of one of the UK's leading clinical AI platforms - [Augnito Omni](#) - today announced that it is offering a free pilot programme to all NHS sites, complete with a no-cost, full cost-benefit analysis report designed to help healthcare leaders make informed, evidence-based decisions on Ambient Voice Technology (AVT) adoption.



Free NHS pilot announced for Augnito Omni, giving healthcare leaders transparent cost-benefit insights into Ambient Voice Technology.

As NHS organisations continue to get bombarded with marketing and sales hype of unsafe and expensive AI tools, the ability to accurately measure the impact of [AI solutions](#) has become essential. Scribetech UK's cost-benefit analysis report is designed specifically to support these priorities, giving NHS teams access to advanced AI tools while also providing transparent data on their effectiveness.

Free Cost-Benefit Analysis for NHS Decision-Makers

Every participating NHS site will receive a comprehensive, free-of-charge cost-benefit analysis, delivered as a formal report. This includes measurement of:

- Time savings across clinical documentation workflows
- Improvements in documentation accuracy and consistency
- Operational efficiencies gained through reduced administrative burden
- Financial impact driven by faster throughput, improved coding (ICD-10 & SNOMED), and

workflow optimisation

- User experience data from clinicians and administrative staff

The analysis is designed to support funding requests, digital transformation cases, and evidence-based decisions on scaling AI-powered solutions.

About Augnito Omni

Augnito Omni is an enterprise-grade clinical AI suite designed for UK healthcare environments, with unique strengths that make it ideally suited to NHS workflows. Key features include:

- Instant patient-note generation with minimal edits
- 99.3% accurate medical speech recognition, trained on over 20 years of NHS and UK medical language data
- Clinical letter and email generation, using customisable templates
- MHRA-certified non-hallucinating clinical feedback through its Scribe Quality & Reliability (SQR) Framework
- Automatic ICD-10 and SNOMED tagging
- Live translation across 37+ medical languages
- Seamless HL7/FHIR integration, enabling deployment within days
- Secure UK-hosted, GDPR-compliant infrastructure with 99.9% uptime

With its UK-specific tuning, safety guardrails, and enterprise reliability, Augnito Omni provides an AI solution that aligns directly with NHS clinical governance and operational requirements.

Supporting NHS Digital Transformation at Zero Cost

The free pilot enables NHS teams to test the AI in live clinical environments, compare performance with existing systems, and explore use cases ranging from documentation support and medical speech recognition to AI-assisted patient communication.

Availability

The no-cost pilot and free cost-benefit analysis are now open to all NHS hospitals, Trusts, and departments. Sites can register their interest and receive a briefing pack outlining the pilot structure, expected outcomes, and results already reported by other NHS organisations.



AUGNITO
from scribetechn⁺

Over two decades of experience supporting NHS clinical documentation and workflow innovation.

About Scribetech

Scribetech is a UK-based health technology provider with over two decades of experience supporting NHS clinical documentation and workflow innovation. Its flagship platform, Augnito Omni, is used across healthcare settings to improve clinical efficiency, reduce administrative burden, and support safer, more reliable patient care through UK-compliant artificial intelligence.

DR JAM GAFAROV

Scribetech UK Ltd

+ +44 7860 351120

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/875078736>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.